Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 24, 2015

Everolimus for Advanced, Non-Functional Neuroendocrine Tumors of the Lung or Gastrointestinal Tract

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Everolimus for the Treatment of Advanced, Non-Functional Neuroendocrine Tumours of the Lung or Gastrointestinal Tract (RADIANT-4): A Randomised, Placebo-Controlled, Phase 3 Study
Lancet 2015 Dec 15;[EPub Ahead of Print], JC Yao, N Fazio, S Singh, et al for the RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group

Further Reading